Stephanie K Tankou, MD, PhD
img_Stephanie K Tankou
ASSISTANT PROFESSOR | Neurology, Multiple Sclerosis
Are you a patient?
Research Topics
Autoimmunity, Immunology, Inflammation, Metabolomics, Microglia, Mucosal Immunology, Multiple Sclerosis, Proteomics
Gut microbiome, Stool proteomics, Gut intestinal permeability, Neurodegeneration, Cognition, Blood brain barrier permeability
It is known that the gut microbiome has a broad influence on health and diseases including infection, atherosclerosis, cancer, inflammatory, metabolic and autoimmune diseases. Alterations in the gut microbiome of MS patients has been reported by several investigators. However, the mechanisms by which the gut microbiota contributes to the pathophysiology of MS remain poorly understood. My laboratory is interested in identifying gut derived bacteria that modulate neuroinflammation and to elucidate their mechanisms of action. This comprehensive analysis will lead to the identification of microbial derived pathways that suppress CNS inflammation. Identification of these bacteria could lead to the discovery of disease biomarkers as well as novel and more efficacious prevention strategies and therapies for relapsing-remitting as well as progressive MS.

MD, Johns Hopkins University School of Medicine

Internship, Internal Medicine, MetroHealth Medical Center

Residency, Neurology, UCLA Medical Center School of Medicine-Urology GME


American Board of Psychiatry and Neurology

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Tankou did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.